Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. - Wikidata - awgldk - TriplyDB

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

http://www.wikidata.org/entity/Q37248065

about

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia Effective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery.Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.Prevalence and predictors of sub-optimal medication adherence among patients with severe mental illnesses in a tertiary psychiatric facility in Maiduguri, North-eastern Nigeria.Maintaining Adherence Programme: evaluation of an innovative service model Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study Patient advocacy: Japanese psychiatric nurses recognizing necessity for intervention.Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation.The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values.Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.Cariprazine: A Review in Schizophrenia.Medication adherence in patients with schizophrenia.Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis.Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients.Schizophrenia: Impact of psychopathology, faith healers and psycho-education on adherence to medications.Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation.The effectiveness of a nursing discharge programme to improve medication adherence and patient satisfaction in the psychiatric intensive care unit.Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review.Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.Exploring service users', carers' and professionals' perspectives and experiences of current antipsychotic prescribing: A qualitative study.GPs' views and perspectives on patient non-adherence to treatment in primary care prior to suicide.Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia.No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.

P2860

Q26745792-16CAF68F-AA37-462B-9E79-31F6A078C614 Q28545127-6F8332EC-7300-4E51-BA15-CFAA89451AC3 Q30276915-F5302C8C-FA8C-41F4-B6F9-5FCD76D31A51 Q30937746-50D215B4-DCE5-4633-922A-0055D1651479 Q33595935-AC727CEA-1D1F-47DC-A511-85316B3BC4D8 Q33650097-07D7224D-F267-4F2E-B3D9-FAF196969B70 Q33759300-A3A1D37B-E6BB-47C3-BB8D-1713FDE38F97 Q34650576-CED54FA3-EC78-48FD-BBED-E476B7B8753D Q35224289-9859781E-3A15-41F6-A737-95EC28C885A9 Q35659829-6D726867-5CE7-4ED9-AAF2-5DB41B953E24 Q35736374-BC41EF61-1D43-4238-981A-31CCF31A92EF Q36042870-AE4D5345-9753-4DC8-88B0-D197471D49C4 Q36623532-5F056931-4061-4091-8799-F93F1E9AA460 Q36992316-9E6E2353-0F8F-4B04-AADE-989F2EC5F85C Q37137799-68E5AAC0-A2CB-4500-8D52-D9EE3EDA6D51 Q37170587-C6C48B66-BE0F-4547-AF36-32A3F2AC1A9E Q37441407-536AC555-910E-466C-A2A4-FA2CC71D9170 Q37547469-12633B11-F3AF-40A9-AC11-A513CF85A417 Q38253168-D115515E-0E20-49AF-AACB-6A6BE753AD3F Q38287203-DA1BD1A9-90A8-4DAD-A961-A433D29C64BB Q38610490-FCAB9392-DE72-46A7-8771-D38741C7E94E Q38613680-896A02BE-E6D9-4F8A-8E5A-00BF8A49A8C3 Q38639268-C10F97F1-88E6-4679-8196-1D834EBCA1C4 Q38697025-0797C13D-6677-445B-B2C0-F6ADC324AA11 Q38754971-17233C9B-CE32-442F-A6F8-8AD81E5D03BD Q38808583-2BE1F956-3DB3-4B36-BE7C-1CD28198977C Q38997108-371B8F22-CD47-4FCA-97A3-E5E3048EC875 Q39126835-B4205249-37C0-4FE4-8788-20C40851C653 Q40309621-820ED987-4BE3-4257-B3EB-313AF2BDBE72 Q40488575-262E264D-D20D-490F-BCCD-2B26568276E4 Q41204400-5B21DB6D-76F0-4929-A087-B5B12EA3D90A Q42659528-03214846-B907-4F45-A0BF-BC6C00C3DF32 Q44697721-732A838D-04F4-4245-B564-087FCD08BF98 Q47431234-3A516305-251D-4EEF-8329-0786A3D10A95 Q47555919-7B6A5F1E-74C5-457D-8E46-D4604C30599E Q47574118-6DC82621-6352-480C-9C92-8F36B9032ACF Q47577273-810CAE22-60EC-499E-B22A-E32976A41F6B Q47688187-32142584-E9B6-4541-9DE4-A95A982AD4D5 Q47699839-C0173EC7-21C3-4A04-8116-5A5E823CABF8 Q47785459-5B98871C-9EB4-4E20-9560-4120513BAF27

P2860

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

http://www.wikidata.org/entity/Q37248065

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Medication adherence in schizo ...... systematic literature review.

@en

Medication adherence in schizo ...... systematic literature review.

@nl

type

label

Medication adherence in schizo ...... systematic literature review.

@en

Medication adherence in schizo ...... systematic literature review.

@nl

prefLabel

Medication adherence in schizo ...... systematic literature review.

@en

Medication adherence in schizo ...... systematic literature review.

@nl

P1433

Q37248065-040575DB-4336-4DF0-ABCB-37C369F69FE2

P1476

Q37248065-98C95E2A-ABCD-4EA2-B6A4-5FED1831E24F

P2093

Q37248065-4857F863-45D6-4DE7-8FCF-C20D3D0515AA

Q37248065-A8E2F293-0D7A-473E-A811-1F52D2FC00F1

Q37248065-AC2D5C31-349E-4519-8DAD-8D29FC20183B

Q37248065-C786FAD7-41E6-41EB-803D-70654E6D9C9F

Q37248065-FA796A96-0FBD-4158-AD9D-1251E8D596DA

P2860

Q37248065-03035D3F-F8F1-4550-B1AB-86B609352974

Q37248065-06669836-1BF3-4CAF-915E-DC6D4D47AE91

Q37248065-12F2F6DD-836B-4533-BD3B-91266BE8BBAD

Q37248065-20EE7316-E918-452B-AB11-4751D0316326

Q37248065-29DFA6CF-D74C-4249-BBEA-BA027B050EB3

Q37248065-3243D98A-CB7E-49F1-A24A-211B9EBB2765

Q37248065-3464E79E-DFDC-4AB5-BD73-B97143A66797

Q37248065-361F076E-B5EB-4708-8E9D-A6F69D651BA4

Q37248065-5B40D85C-F4BE-4ECB-91B4-34751C7C373C

Q37248065-71F9694A-B9D1-4885-BA96-327F5D4ABEA7

P304

Q37248065-14C0AF34-AC0C-4B9D-AF49-922112ED4C65

P31

Q37248065-1E7F9248-C54F-4A96-8828-040499E43BB0

P356

Q37248065-8C637B0B-88CC-4B31-8D3D-02A4687CFAD6

P433

Q37248065-4E721F6C-E5BD-4125-8917-E30A9BCB4C08

P478

Q37248065-71979D05-5C99-4DAF-8A2B-644094C9B2B1

P50

Q37248065-53D5A891-711E-4DF8-ABF9-E9BF3E3AC3CE

P577

Q37248065-62139E5F-41C5-4777-BA74-D96C6ECA0133

P5875

Q37248065-6C243B49-3513-4A8D-8409-60A38F684800

P698

Q37248065-F819E266-FF73-4884-97B1-3546213CEDE4

P921

Q37248065-5260634A-E709-49EF-89E9-BF36520CC9A9

P932

Q37248065-8310119D-CE83-4092-94F5-4AE4C637E5FB

P356

2045125312474019

P1433

Therapeutic advances in psychopharmacology

P1476

Medication adherence in schizo ...... systematic literature review.

@en

P2093

Kavi J Littlewood

http://www.w3.org/2001/XMLSchema#string

Kyoko Higashi

http://www.w3.org/2001/XMLSchema#string

Marc De Hert

http://www.w3.org/2001/XMLSchema#string

Ola Granström

http://www.w3.org/2001/XMLSchema#string

Teresa Diez

http://www.w3.org/2001/XMLSchema#string

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.

Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.

Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis.

P304

200-218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2045125312474019

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258118040

http://www.w3.org/2001/XMLSchema#string

P698

24167693

http://www.w3.org/2001/XMLSchema#string

P921

P932

3805432

http://www.w3.org/2001/XMLSchema#string